US filing the first worldwide for JT/GSK's MEK inhibitor for melanoma
This article was originally published in Scrip
Executive Summary
Japan Tobacco's trametinib has been filed for approval in the US by global licensee GlaxoSmithKline, for the treatment of unresectable or metastatic melanoma. The filing is the first to be made worldwide for the MEK inhibitor, JT in Japan told Scrip.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports